Acanthocytosis
Abscess
Acetylcholine receptor antibody
Acetylsalicylic acid
Acetazolamide
Akathisia
Adrenoleukodystrophy
Adrenal hyperplasia
Acquired immune deficiency syndrome-related complex (ARC)
Adrenocorticotropic hormone
Adrenomyeloneuropathic syndrome
Allopurinol
Alzheimer's disease
Adrenergic hyperplasia
Adrenocorticotropic hormone
Adrenoleukodystrophy
Early-onset, clinical predictors of institutionalization and death, 980 (June)
Acquired immune deficiency syndrome-related complex (ARC)
Adrenocorticotropic hormone
Adrenomyeloneuropathic syndrome
Allopurinol
Alzheimer's disease
Adrenergic hyperplasia
Adrenocorticotropic hormone
Adrenoleukodystrophy
Early-onset, clinical predictors of institutionalization and death, 980 (June)
Amyotrophic lateral sclerosis
Antineural antibodies in the serum of patients with, 152 (Jan.)
brain glutamate deficiency in, 1845 (Dec.)
fast axonal transport in, an intra-axonal organelle traffic analysis, 738 (May)
motor neuron disease and paraproteinemia, 335 (Feb.)
occurrence function in patients in respirators (Clinical/Scientific Note), 1431 (Aug.); correction, 1606 (Oct.)
physiologic and metabolic response to progressive and prolonged exercise in, 1217 (July)
potential therapies for (Letter), 544 (Mar.)
reduction in insulin receptors in, correlates with reduced insulin sensitivity, 1375 (Aug.)
respiratory failure in, role of intermittent negative pressure ventilation in treatment of, 1874 (Dec.)
size-dependent myelin fibrillar loss in the corticospinal tract in, and Shy-Drager syndrome, 529 (Mar.)
skeletal fracture history and, case-control study, 717 (Apr.)
thyrotropin-releasing hormone and (Letter), 175 (Jan.)
thyrotropin-releasing hormone, intrathecal, pharmacokinetics of, 597 (Apr.)
trauma and (Correspondence), 1296 (July)
treatment of, with TRH analog DN-1417, 715 (Apr.)

Anemia
chronic hemolytic, chorea-amyotrophy with, variant of chorea-amyotrophy with acanthocytosis, 645 (Apr.)

Angiography
carotid arteries, comparison of, in unilateral cerebral ischemia, 1027 (June)
spinal cord, vascular malformations of, intrathecal perimedullary arterial-venous fistulas fed by medullary arteries, 969 (June)

Ankle
position sense of, quantitative assessment, functional approach, 89 (Jan.)

Anticholinergics
sustained-release, in dystonia (Clinical/Scientific Note), 885 (May)

Anticonvulsants
effect of, on glutamate neurotoxicity in cortical cell culture, 319 (Feb.)

Antifibrinolytic therapy
cerebral ischemia, predicting of, after aneurysmal subarachnoid hemorrhage, 1027 (June)

Antineuronal antibodies
serum in patients with amyotrophic lateral sclerosis, 152 (Jan.)

Aphasia
acquired, in childhood, clinical and computed tomography investigations, 1165 (July)
chronic, cerebellar glucose metabolism in, 1599 (Oct.)
epilepsy and (Correspondence), 1571 (Sept.)
global, without hemiparesis (Correspondence), 1691 (Oct.)
global, without hemiparesis, multiple etiologies, 201 (Feb.)
nonfamilial dysphasic dementia, reduced somatosensin-like immunoreactivity in cerebral cortex in, 1448 (Sept.)

Anemia
mitochondrial encephalomyopathy, ataxia and (Clinical/Scientific Note), 1429 (Aug.)

Anemia syndrome
sleep, bimodality electrophysiologic evaluation of brainstem in, 1036 (June)

Apocereuloplasmin deficiency
familial, associated with biepharosperm and retinal degeneration, 761 (May)

Apomorphine
diurnal responsiveness to, Parkinson’s disease, 1250 (July)

Apraxia
callosal, 100 (Jan.)
Argininosuccinic aciduria
diagnosis of, after valproic acid-induced hyperammonemia (Clinical/Scientific Note), 886 (May)

Arteries
atherosclerotic carotid artery disease, symptoms of amaurosis fugax in, 829 (May)
basilar artery, middle and distal segments of, stenosis of, 1742 (Nov.)
brachial artery-aneurysm vein shunts, brachial neuropathy after, for chronic hemodialysis, 1398 (Aug.)
carotid, angiographic comparison of, in unilateral cerebral ischemia, 1027 (June)
cerebral arteriovenous malformations, unruptured, surgery for, 279 (Feb.)
cerebral arteriovenous malformations, unruptured, treatment of, 815 (May)
cerebral, ischemic infarction, brain calcium content in, in rat, 1227 (July)
cerebral vasoconstriction, toxemia and, 1555. (Sept.)
internal carotid artery stenosis, asymptomatic, follow-up (Correspondence), 889 (May)

Arteriogenous malformations
unruptured, surgical therapy and, 279 (Feb.)
unruptured, treatment of, 815 (May)

Artery-to-artery embolism
stroke in the posterior circulation caused by, 292 (Feb.)

Ataxia
familial, abnormal ocular motor function predicts clinical diagnosis of, 698 (Apr.)
Friedreich’s, variant form, with vitamin E deficiency and normal fat absorption, 68 (Jan.)
infantile X-linked, deafness and, new clinicopathologic entity, 1344 (Aug.)
mitochondrial encephalomyopathy, sleep apneas and (Clinical/Scientific Note), 1429 (Aug.)
MRI in Miller Fisher variant of Guillain-Barré syndrome (Clinical/Scientific Note), 1431 (Aug.)
spinocebellar, familial, and Alzheimer’s disease, or atypical Gerstmann-Strasslers syndrome, 269 (Feb.)
X-linked recessive inheritance of, and adult-onset dementia, clinical features and preliminary linkage analysis, 602 (Apr.)

Atherosclerotic carotid artery disease
symptoms of amaurosis fugax in, 829 (May)

Atrophy
multispinal muscular, pedigree with protanopia and, 1019 (June)

Attention
right hemisphere lesions, lack of heart rate changes during an attention-demanding task after, 624 (Apr.); correction, 748 (May)

Auscultation
cerebral, origin of a forgotten art, (Historical Neurology) 1523 (Sept.)

Automobile accident
risk of, with seizures occurring while driving, relation to seizure type, 1613 (Oct.)

Autopsy
concern over rate of, 22A (Jan.)
dementia, and clinical study of, in Olmsted County, Minnesota, 1980-1981, 426 (Mar.)
Pick’s disease, positron emission tomography and histopathology in, 439 (Aug.)

Awards and prizes
American Academy of Neurology, Research Fellowship awardees, 22A (Mar.)
Jevins Investigators named by NINCDS, 28A (Mar.)
Kevin D. Barron to be Srinivasan Lecturer for 1988, 25A (Nov.)
Lawrence C. McHenry Award to Alan Pestronk, 26A (July)
Medical College of Pennsylvania National Board Award to Kathleen M. Foley, MD, 31A (June)
Pfizer announces Award for Innovation, 24A (Jan.)
Potamkin prize for Alzheimer’s disease announced, 25A (July)
Sarah L. Poiley Memorial Award to J. William Langston, 26A (Apr.)

Axonal transport
fast, in amyotrophic lateral sclerosis, intra-axonal organelle traffic analysis, 738 (May)

B

Back pain
cancer patient and, algorithm for evaluation and management of, 134 (Jan.)

Baclofen
β-baclofen and racemic baclofen, comparison of, in trigeminal neuralgia, 1725 (Nov.)

Barbiturate abuse
status epilepticus, nonconvulsive, and (Correspondence), 1288 (July)

Behavioral neurology
perseveration in, 1736 (Nov.)

Benzodiazepine
receptor complexes in frontal cerebral cortex, increased number and altered regulation of, Huntington’s disease, 916 (Sept.)

Biopsy
adrenoleukodystrophy, electronmicroscopic study on rectal mucosa in, 1012 (June)
computer-assisted stereotaxic, diagnosis of primary central nervous system lymphoma, 1160 (July)
cortical, results of, in Alzheimer’s disease, correlation with cognitive deficits, 1201 (July)
muscle, extracts of, from patients with spinal muscular atrophies inhibit neurite outgrowth from spinal neurons, 1381 (Aug.)
skin, immunoglobulin deposits in peripheral nerve endings detected by, in patients with IgM M proteins and neuropathy, 363 (Feb.)

Birth injury
glossolaryngeal paresis induced by, 533 (Mar.)

Bloch-Sulzberger syndrome
incontinentia pigmenti, anterior horn cell degeneration association with, 446 (Mar.)

Blood
anemia, chronic hemolytic, chorea-amyotrophy with, variant of chorea-amyotrophy with acanthocytosis, 645 (Apr.)

blood T-cell phenotypes, peripheral, serial analysis of, and myelin basic protein reactivity in experimental allergic encephalomyelitis, 719 (Apr.)
glucose levels in, after cardiac arrest (Correspondence), 1267 (July)
hypercoagulability, acute stroke and, prognostic significance, 1967 (Oct.)
leukemia, acute monoblastic, in hematologic remission, infiltrative polyneuropathy due to, 474 (Mar.)
leukemia, central nervous system complications of a newly recognized sub-
cerebral cortex, Alzheimer's disease, substance P-like immunoreactivity is reduced in, 1205 (July)
cerebral cortex, frontal, increased number and altered regulation of benzodiazepine receptor complexes in, Huntington's disease, 916 (June)
cerebral cortex, reduced somatostatin-like immunoreactivity in, in non-familial dyspepsia, 1448 (Sept.)
cerebral cortex, reductions in corticotropin releasing factor-like immunoreactivity in, in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy, 905 (June)
cerebral dominance, sex, and callus size in MRI, 1385 (Aug.)
cerebral ischemia, predicting of, after aneurysmal subarachnoid hemorrhage, influences of clinical condition, CT results, and antifibrinolytic therapy, 1586 (Oct.)
cerebral ischemia, unilateral, angiographic comparison of carotid arteries in, 1957 (June)
cerebral perfusion, regional variation in, during acute hypertension, 94 (Jan.)
cerebral plexus, bilateral, 1043 (June)
cerebral vasocostriction, in toxemia, 1555 (Sept.)
cerebroendolysoma, diagnosis and treatment of (Correspondence), 1001 (June)
cerebrovascular disease, ischemic, headache in (Correspondence), 1266 (July)
cerebrovascular disease, lipoprotein(a) in ischemic, new approach to the
cerebral ischemia, predicting of, after aneurysmal subarachnoid hemorrhage, influences of clinical condition, CT results, and antifibrinolytic therapy, 1586 (Oct.)
cerebral ischemia, unilateral, angiographic comparison of carotid arteries in, 1957 (June)
cerebral perfusion, regional variation in, during acute hypertension, 94 (Jan.)
cerebral plexus, bilateral, 1043 (June)
cerebral vasocostriction, in toxemia, 1555 (Sept.)
cerebroendolysoma, diagnosis and treatment of (Correspondence), 1001 (June)
cerebrovascular disease, ischemic, headache in (Correspondence), 1266 (July)
cerebrovascular disease, lipoprotein(a) in ischemic, new approach to the
cerebral ischemia, predicting of, after aneurysmal subarachnoid hemorrhage, influences of clinical condition, CT results, and antifibrinolytic therapy, 1586 (Oct.)
cerebral ischemia, unilateral, angiographic comparison of carotid arteries in, 1957 (June)
cerebral perfusion, regional variation in, during acute hypertension, 94 (Jan.)
cerebral plexus, bilateral, 1043 (June)
cerebral vasocostriction, in toxemia, 1555 (Sept.)
cerebroendolysoma, diagnosis and treatment of (Correspondence), 1001 (June)
cerebrovascular disease, ischemic, headache in (Correspondence), 1266 (July)
cerebrovascular disease, lipoprotein(a) in ischemic, new approach to the

Crohn’s disease
peripheral neuropathy associated with, 1414 (Aug.)

Cytomegalovirus
encephalitis associated with, 1414 (Aug.)

Cyclosporin A toxicity
iNTRICALLY, chronic, complicating treatment of chronic inflammatory
demyelinating polyradiculoneuropathy, 147 (Jan.)

Dementia
adult-onset, X-linked recessive inheritance of ataxia and, clinical features
and preliminary linkage analysis, 802 (Apr.)
Alzheimer’s disease, absence of neurophysiologic effect of lecithin in, by EEG
topography, 1015 (June)
Alzheimer’s disease, atypical Gerstmann-Straussler syndrome or familial
spinocerebellar ataxia and, 269 (Feb.)
Alzheimer’s disease, cerebral blood flow in severity-matched patients with,
and multi-infarct patients, 431 (Mar.)
Alzheimer’s disease, cerebral cortex in, substance P-like immunoreactivity is
reduced in, 1205 (July)
Alzheimer’s disease, cerebrospinal fluid concentrations of corticotropin-re-
leasing hormone and corticotropin are reduced in, 535 (Mar.)
Alzheimer’s disease, clinical and family study of 22 twin pairs, 359 (Mar.)
Alzheimer’s disease, cortical biopsy results in, correlation with cognitive
function and cortical metabolism, 161 (Jan.)
Alzheimer’s disease, dopamine agonist therapy for, in humans, 1765 (Nov.)
Parkinson’s disease and dementia, norepinephrine and, dopamine in locus
caeruleus, 42 (Jan.)

Dopamine
incemic striatal injury, role of, in, metabolic evidence, 1712 (Nov.)
neglect, dopamine agonist therapy for, in, 1765 (Nov.)
Parkinson’s disease, reduction in, correlates with, in locus, 1375 (Aug.)
Parkinson’s disease, forms of, in patients with, 1009 (June)

Dystonia
cranial-cervical, botulinum A toxin for, double-blind, placebo-controlled
study, 616 (Apr.)

Ear
defeasibility, infantile X-linked ataxia and, new clinicopathologic entity, 1344
(Aug.)

Eating-Lambert syndrome
myasthenia gravis combined with, overlap myasthenic syndrome, 1411
(Aug.)

Electrocardiography (ECG)
epilepsy, abnormalities in patients with, 1624 (Oct.)
Electroconvulsive therapy (ECT)
memory disturbances induced by, physostigmine improves, 871 (May)
Electroencephalography (EEG)
Alzheimer's disease, absence of neurophysiologic effect of lectin in, by, 1015
(June)
intracranial daytime monitoring and prolonged intensive and ambulatory mon-
toring compared (Correspondence), 1899 (Dec.)
localizing deep intracranial voltage sources by scalp-recorded (Letter), 176
(Jan.)
monitoring, daytime intensive, comparison with prolonged intensive and
ambulatory monitoring, 483 (Mar.)
pregnant fetus, positive rolandic sharp waves in, 1481 (Sept.)
quantitative, American EEG Society statement on clinical use of, 27A (May)
seizures, complex partial, in children, ictal manifestations and their relation
to clinical course, 1378 (Aug.)
stroke, evaluation of, using EEG frequency analysis and topographic map-
ing, 1153 (July)
Electromyography (EMG)
meningoradiculoneuritis, tick-bite, clinical, electrophysiologic, and histo-
logic findings in 10 cases, 749 (May)
Miller Fisher syndrome, neuropathy in, clinical and electrophysiologic find-
ings, 1493 (Sept.)
orthostatic tremor and (Correspondence), 1434 (Aug.)
single-fiber, is a sensitive indicator of axonal degeneration in diabetes, 1394
(Aug.)
Emboli
artery-to-artery, stroke in the posterior circulation caused by, 292 (Feb.)
Encephalitis
cytomegalovirus, associated with episodic neurologic deficits and OKT-8
+ psicotosis, 149 (Jan.)
herpes simplex, early diagnosis of, by magnetic resonance imaging, 173 (Feb.)
herpes simplex, in third trimester of pregnancy, successful outcome for
mother and child, 1514 (Sept.)
subacute, acquired immune deficiency syndrome, and its relation to HTLV-
III infection, 562 (Apr.)
Encephalomyelitis
experimental allergic, serial analysis of peripheral blood T-cell phenotypes
and myelin basic protein reactivity in, 719 (Apr.)
Encephalomyopathy
See also Brain
mitochondrial, stacking, sleep apnea and (Clinical/Scientific Note), 1429
(Aug.)
Encephalomyopathy
See also Brain
neuroradiologic features of, 1687 (Sept.)
multiple sclerosis, clinical changes in, predicted by, drug study, 1754
(Oct.)
refractory status epilepticus, pentobarbital treatment of, 500 (May)
seizure, breakthrough, following substitution of Depakene capsules (Abbott)
with generic valproic acid (Clinical/Scientific Note), 1885 (Dec.)
stroke and, 1209 (July)
Escherichia coli
brainstem auditory, phenytoin effect on (Correspondence), 1687 (Oct.)
Esotropia
“Do Not Resuscitate” orders and, 1079 (June)
vegetative state, Brophy case (Editorial), 1359 (Aug.)
Epilepsy
absence epilepsies, concepts of, discrete syndromes or biological continuum?
599 (Nov.)
augmentin and (Correspondence), 1691 (Oct.)
ti perineuronal net formation (Correspondence), 1571 (Sept.)
 cortical resection for, complete or partial, clinical outcome after, 1934
(Oct.)
limbic evoked potentials predict site of epileptic focus, 494 (Mar.)
mesial frontal lobe seizure foci, epileptic syndrome caused by, 577 (Apr.)
monitoring, daytime intensive, compared with prolonged intensive and
ambulatory monitoring, 483 (Mar.)
partial seizures, controlled study of progabide in, 963 (June)
pharmacology, phenytoin and carbamazepine, alone and in combination,
toxicant and neurotoxic effects, 1111 (July)
psychotropic medications, effect of, on seizure control in patients with, 1525
(Sept.)
respiratory depression, pentobarbital treatment of, 500 (May)
seizure, breakthrough, following substitution of Depakene capsules (Abbott)
with generic valproic acid (Clinical/Scientific Note), 1885 (Dec.)
stroke and, 1209 (July)
Ethanol
caffeine and, 169 (Jan.)
kinetic predominant, successful treatment with clonazepam, 471 (Mar.)
Review of, 1194 (July)
Ethics
“Do Not Resuscitate” orders and, 1079 (June)
vegetative state, Brophy case, 1357 (Aug.)
F3 event-related potentials, cholinergic modulation of, in humans, 346
(Apr.)
Hypertension
short-latency somatosensory, bipolar recording of, median nerve stimu-
lation, 410 (Mar.)
paraparesis, tropical spastic, Seychelles Islands, clinical and case-control
neuropadiatric study, 1323 (Aug.)
Parkinson's disease, acquired, evidence from a geographic comparison with
multiple sclerosis, 467 (Mar.)
Parkinson's disease, prevalence of, in the Republic of San Marino, 1679
(Oct.)
seizures, absence, risk factors for, population-based case-control study in
Rochester, Minnesota, 1309 (Aug.)
seizures, generalized tonic-clonic, risk factors for, population-based case-
control study in Rochester, Minnesota, 1315 (Aug.)
stroke, acute, prognosis of, 221 (Feb.)
stroke, risk factors for recurrent, Lehigh Valley study of, 503 (Mar.)
Epidemiology

crusted-Jakob disease, conclusion of a 15-year investigation in France
and review of world literature, 895 (June)
crusted-Jakob disease (Correspondence), 1821 (Nov.)
Guillain-Barré syndrome, risk factors for, 685 (Apr.)
motor neuron disease, United States, 1971 and 1973-1978, patterns of mor-
tality and associated conditions at the time of death, 1339 (Aug.)
multiple sclerosis, incidence of antibody to HTLV-I is not increased in
Japanese patients with, 156 (Jan.)
muscle atrophy, population differences in disease expression and acetylcholine
receptor antibody titers between Chinese and Caucasian, 1854 (Dec.)

December 1987 NEUROLOGY 37 1899
somatosensory, cervical synapse-dependent, following posterior tibial nerve stimulation, 1417 (Aug.)
somatosensory, cortical generators of, to median nerve stimulation, 1141 (July)
somatosensory, in chronic acquired demyelinating peripheral neuropathy, 213 (Feb.)
spinal and subcortical somatosensory, human, effect of movement on, 650 (Apr.)
visual, amplitude difference between, after left and right hemifield stimulation in normal subjects, 795 (May)
visual electrical, evaluation of ocular injuries, 123 (Jan.)
visual, usefulness of different stimuli in, 656 (Apr.)

**Exercise**
amyotrophic lateral sclerosis, physiologic and metabolic response to probenecid, 1515 (Sept.)
blepharospasm and retinal degeneration, familial apoceruloplasmin deficiency associated with, 761 (May)
contrast visual testing, neurovisual diagnosis, 923 (June)
eyelid ptosis, bilateral cerebral, 1043 (June)
herpes zoster ophthalmicus, ipsilateral intracerebral hemorrhage, delayed, and (Clinical/Scientific Note), 1264 (July)
huntington's disease, saccades in, initiation defects and distractibility, 364 (Mar.)
hyperactive vestibulo-ocular reflex, cerebellar degeneration, pathogenesis and treatment, 53 (Jan.)
initial motionless stare, surgical outcome following temporal lobectomy and, intractable complex partial seizures, 1355 (July)
lateral eye position, paroxysmal spontaneous nystagmus and vertigo evoked by, 1553 (Sept.)
Leber's congenital amaurosis, rhodanese activity in leukocytes from patients with, enzyme characterization and activity levels, 1879 (Dec.)
nystagmus, pathologic, ethanol-induced resolution of (Clinical/Scientific Note), 887 (May); correction, 1298 (July)
nystagmus, upbeat, clinicopathologic study of two patients, 491 (Mar.)
oculomotor function, in patients in respirators, amyotrophic lateral sclerosis and, 263 (Feb.)
oculomotor function, in patients with, enzyme characterization and activity levels, 1879 (Dec.)
oculomotor function, abnormal, predicts clinical diagnosis of familial ataxia, 698 (Apr.)
ocular motor palsies, familial recurrent Bell's palsy with, 1369 (Aug.)
ocular motor function, in patients with, enzyme characterization and activity levels, 1878 (Dec.)
Machado-Joseph disease, search for a physiologic marker of, 112 (Jan.)
McArdle's disease, two generations, autosomal recessive transmission with manifesting heterozygote, 1558 (Sept.)
myokymia, timber rattlesnake venom-induced, evidence for peripheral nerve origin, 1545 (Sept.)
Parkinson's disease, orofacial motor control impairment in, 394 (Mar.)
parechymal atrophy, periventricular, secondary to atrophy of the globus pallidus, 325 (Feb.)
peripheral nerve glycolipids, 1795 (Nov.)
paraproteinemia, neuropathy and, differential binding of IgM M-proteins to peripheral nerve glycolipids, 1795 (Nov.)

**Eye**
amyotrophic lateral sclerosis, physiologic and metabolic response to probenecid, 1515 (Sept.)
blepharospasm and retinal degeneration, familial apoceruloplasmin deficiency associated with, 761 (May)
contrast visual testing, neurovisual diagnosis, 923 (June)
eyelid ptosis, bilateral cerebral, 1043 (June)
herpes zoster ophthalmicus, ipsilateral intracerebral hemorrhage, delayed, and (Clinical/Scientific Note), 1264 (July)
huntington's disease, saccades in, initiation defects and distractibility, 364 (Mar.)
hyperactive vestibulo-ocular reflex, cerebellar degeneration, pathogenesis and treatment, 53 (Jan.)
initial motionless stare, surgical outcome following temporal lobectomy and, intractable complex partial seizures, 1355 (July)
lateral eye position, paroxysmal spontaneous nystagmus and vertigo evoked by, 1553 (Sept.)
Leber's congenital amaurosis, rhodanese activity in leukocytes from patients with, enzyme characterization and activity levels, 1879 (Dec.)
nystagmus, pathologic, ethanol-induced resolution of (Clinical/Scientific Note), 887 (May); correction, 1298 (July)
nystagmus, upbeat, clinicopathologic study of two patients, 491 (Mar.)
oculomotor function, in patients with, enzyme characterization and activity levels, 1878 (Dec.)
oculomotor function, abnormal, predicts clinical diagnosis of familial ataxia, 698 (Apr.)
ocular motor palsies, familial recurrent Bell's palsy with, 1369 (Aug.)
ocular motor function, in patients with, enzyme characterization and activity levels, 1878 (Dec.)
Machado-Joseph disease, search for a physiologic marker of, 112 (Jan.)
McArdle's disease, two generations, autosomal recessive transmission with manifesting heterozygote, 1558 (Sept.)
muscular dystrophy, Duchenne and Becker, use of serum creatine kinase, pyruvate kinase, and genetic linkage for carrier detection in, 4 (Jan.)
muscular dystrophy, Duchenne, carrier assessment for mothers and sisters of isolated cases, importance of serum enzyme determinations, 1478 (Sept.)
muscular dystrophy, Duchenne, comparison of, and normal myoblasts from a heterozygote, 675 (Apr.)
muscular dystrophy, Duchenne, monocytic female twin carries discordant for the clinical manifestations of, 1147 (July)
muscular dystrophy, Duchenne, prenatal detection of, deletion allele (Letter), 355 (Feb.)
myopathy, congenital, biochemical and immunologic studies in a case of, with unusual morphologic features, 1658 (Oct.)
neuronal disease, progressive, and chronic idiopathic intestinal pseudo-obstruction, 1946 (April)
neuropathy, hereditary motor and sensory, X-linked, half-century follow-up, 1460 (Sept.)
proptosis and bulbar muscular atrophy, pedigree with, 1019 (June)
spinal muscular atrophy, a new case of, 910 (June)
spinal muscular atrophies, extracts of muscle biopsies from patients with, inhibit neurite outgrowth from spinal neurons, 1361 (Aug.)
spinocerebellar ataxia and Alzheimer's disease, or atypical Gerstmann-Sträussler syndrome, 289 (Feb.)

**Fistulas**
intrathecal perimедullary arteriovenous, fed by medullary arteries, vascular malformations of the spinal cord, 969 (June)

**Flunarizine**
extrapyramidal reactions induced by, and cinnarizine, 88 (May)

**Foot**
medial plantar neuropathy, 1408 (Aug.)

**Friedrich's ataxia**
variant form, with vitamin B deficiency and normal fat absorption, 88 (Jan.)

**Gamma-G globulin**

**Go**
cerebrospinal fluid synthesis rate of, in multiple sclerosis (Correspondence), 1887 (Dec.)
intraneuronal, in the central nervous system, uptake by retrograde axonal transport, 1780 (Nov.)
macrophage inflammation, peripheral neuropathy in, incidence and antigen-specificity of M proteins, 1506 (Sept.)
multiple sclerosis, immunoblot detection of oligoclonal antimyelin basic protein IgG antibodies in cerebrospinal fluid in, 1515 (Sept.)
oligoclonal, in tears, 853 (May)
paraproteinemia, neuropathy and, differential binding of IgM M-proteins to peripheral nerve glycolipids, 1795 (Nov.)
synthesis rate of, in evaluation of multiple sclerosis in a community hospital, 847 (May)

**Gammopathy**

Gammopathy, demyelinating, due to primary, kappa B cell lymphoma of peripheral nerve, 1231 (July)

**Gamma M globulin**

experimental demyelination of nerve induced by serum of patients with neuropathy and anti-MAG, 242 (Feb.); paraproteinaemia, neuropathy and, differential binding of IgM M-proteins to peripheral nerve glycolipids, 1795 (Nov.)

**Gamma M globulin M-protein**

Ganglioside storage

Sandhoff's disease, adult, hexosaminidase lability, urinary oligosaccharides and, in, 75 (Jan.)

**Gastric restriction surgery**

neuropathic complications after, for morbid obesity, 196 (Feb.)

**Gerstmann-Straussler syndrome**

typical, or familial spinocerebellar ataxia and Alzheimer's disease, 269 (Feb.)

Gilles de la Tourette's syndrome

confused with St. Vitus' dance by Arthur Conan Doyle (Correspondence), 1821 (Nov.)

rating scale for, description, reliability, and validity data, 1542 (Sept.)

treatment of, eight-year, practice-based experience in a predominantly adult population, 1928 (Dec.)

**Glialia**

canine, magnetic resonance brain tumor imaging in, 1235 (July)

intracerebral, xenotransplanted, intravenous adenosine selectively increases blood flow to, 1970 (Dec.)

**Glomerulonephritis**

membranous, chronic progressive demyelinating neuropathy associated with, 342 (Feb.)

**Glucosylsphingosylparae**

birth injury-induced, 533 (Mar.)

**Glucose**

blood levels of, after cardiac arrest (Correspondence), 1267 (July)

cerebral metabolism of, in chronic asphyxia, 1599 (Oct.)

utilization rate of, versus brain size, in humans, 983 (Apr.)

**Glucose utilization**

cerebral, local, coupled forebrain increases of, and blood flow during physiologic stimulation of a somatosensory pathway, in rat, 11 (Jan.)

**Glutamate deficiency**

brain, amyotrophic lateral sclerosis and, 1845 (Dec.)

**Glutamate dehydrogenase**

malate dehydrogenase activities and, in Joseph disease and olivopontocerebellar atrophy, 106 (Jan.)

olivoponto- cerebellar atrophy and (Correspondence), 1687 (Oct.)

**Glutamate neurotoxicity**

effect of anticonvulsant drugs on, in cortical cell culture, 319 (Feb.)

**Glutaric aciduria type 1**

clinical heterogeneity and neuroradiologic features of, 1654 (Oct.)

**Glycogen**

muscular enzyme deficiencies involving glycogenolysis and glycogenesis, phosphorus NMR spectroscopy study of, 983 (Apr.)

**Glycogenosis**

type V, hyperuricemia in (Correspondence), 728 (Apr.)

Gowers, William R.

correspondence with Charcot (Classics in Neurology), 451 (Mar.)

**Growth hormone**

effect of electrical stimulation of medial temporal lobe structures in epileptic patients upon, and ACTH and prolactin, 299 (Feb.)

human pituitary, from cadavers, neurologic disease in ten recipients, 1211 (July)

pituitary, istrogenic Creutzfeldt-Jakob disease and, 1520 (Sept.)

Guillain-Barré syndrome

acquired immune deficiency syndrome, cytomegalovirus polyradiculoneuropathy in, 557 (Apr.)

activated complement components C3a and C5a in cerebrospinal fluid, 1006 (June)

brainstem involvement in (Correspondence), 881 (May)

membranous glomerulonephritis associated with chronic progressive demyelinating neuropathy, 342 (Feb.)

Miller Fisher syndrome, neuropathy in, clinical and electrophysiologic findings, 1495 (Sept.)

Miller Fisher variant of, MRI in (Clinical/Scientific Note), 1431 (Aug.)

polyneuropathy, acute "axonal" (Letter), 357 (Feb.)

quantitative measurement of plasma exchange therapy, 837 (May)

risk factors for, 685 (Apr.)

seroconversion for anti-HTLV-III associated with (Letter), 544 (Mar.)

H

Hallucinosis

brainstem auditory (Clinical/Scientific Note), 1885 (Oct.)

Hand

cheiro-oral syndrome, case report (Clinical/Scientific Note), 1564 (Sept.)

Hand tremor

synergism and, dysregulation of voluntary expiratory muscles, 117 (Jan.)

Handedness

left-hand bias in female congenital adrenal hyperplasia patients, hormones and, 711 (Apr.)

**Head**

direction of turning of, during seizures, significance of (Correspondence), 1092 (June)

turning of, and eye turning in seizures, significance of, 1617 (Oct.)

**Head trauma**

amyotrophic lateral sclerosis and (Correspondence), 1266 (July)

cervical spine fractures, delayed abducens nerve palsies associated with (Clinical/Scientific Note), 1565 (Sept.)

repuducative paramnesia, delayed, 701 (Apr.)

vertigo, benign positional, clinical and oculographic features in 240 cases, 371 (Mar.)

**Headache**

chronic, elexeroceptive suppression of temporalis muscle activity in, 1834 (Dec.)

ischemic cerebrovascular disease and (Correspondence), 1266 (July)

migraine, amaurosis fugax and thrombocytopenia (Clinical/Scientific Note), 1888 (Dec.)

**Health Care Financing Administration**

ASIM opposes release of hospital-specific mortality data, 25A (Nov.)

**Heart**

cardiac arrest, blood glucose levels after (Correspondence), 1267 (July)

cardiomyopathy, mental retardation, and autophagic vacuolar myopathy, 1065 (June)

cardiopulmonary arrest, delayed hippocampal damage in humans following, 1281 (Aug.)

electrocardiography, abnormalities of, in patients with epilepsy, 1624 (Oct.)

heart block, complete, and trigeminal neuralgia (Clinical/Scientific Note), 1089 (June)

heart rate changes, lack of, during an attention-demanding task after right hemisphere lesions, 824 (Apr.); correction, 748 (May)

Parkinson's disease, autonomic function in patients with, relates to duration of disease, 1173 (July)

**Heatstroke**

neurologic manifestations of, at the Mecca pilgrimage, 1004 (June)

**Hematoma**

nontraumatic spinal epidural and subdural, 1381 (Aug.)

**Hemiballism**

striatal hemorhage and (Clinical/Scientific Note), 1428 (Aug.)

**Hemifacial spasm**

due to cerebellopontine angle lipoma, case report, 337 (Feb.)

due to contralateral acoustic neuroma, case report, 339 (Feb.)

**Hemiparesis**

acute, infantile herpes zoster ophthalmicus and, following intrauterine chickenpox, 1537 (Sept.)

aphasia, global, without (Correspondence), 1691 (Oct.)

**Hemodialysis**

chronic, brachial artery-antecubital vein shunts for, brachial neuropathy after, 1398 (Aug.)

**Hemorrhage**

aneurysmal subarachnoid, predicting cerebral ischemia after, influences of clinical condition, CT results, and antifibrinolytic therapy, 1596 (Oct.)

dorsal mesencephalic, small (Correspondence), 730 (Apr.)

intracerebral, delayed ipsilateral, herpes zoster ophthalmicus and (Clinical/Scientific Note), 1264 (July)

intracerebral, dental chair, 511 (Mar.)

intracerebral, phenylpropanolamine use and, 399 (Mar.)

intracranial, postpartum, phenylpropanolamine use and (Correspondence), 1686 (Oct.); correction, 1890 (Dec.)

intraventricular, positive rolandic sharp waves in the EEG of the premature infant, 1481 (Sept.)

lateral pontine tegmental, presenting as isolated trigeminal sensory neuropathy, 704 (Apr.)

stratial, hemiballism after (Clinical/Scientific Note), 1428 (Aug.)

**Hepatitis B**

infection

polyneuropathy, chronic relapsing demyelinating, associated with, 1663 (Oct.)

**Herpes simplex encephalitis**

eye diagnosis of, by magnetic resonance imaging, 179 (Feb.)

pregnancy, third trimester, successful outcome for mother and child, 1534 (Sept.)

**Herpes simplex virus type 2**

myelopathy, acute ascending necrotizing, caused by, 1791 (Nov.)

**Herpes zoster ophthalmicus**

infantile, acute hemiparesis and, following intrauterine chickenpox, 1537 (Sept.)

ipsilateral intracerebral hemorrhage, delayed, and (Clinical/Scientific Note), 1264 (July)

**December 1987 NEUROLOGY 37 1901**
Hexosaminidase deficiency

Historical Neurology: See also Classics in Neurology and Historical Neurology

Alban G. Smith and the beginnings of spinal surgery, 1683 (Oct.)

Inclusion body myositis

Interferon
gamma, multiple sclerosis treatment with, 1097 (July)

Kearns-Sayre syndrome
mitochondrial studies in, normal respiratory chain function with absence of a mitochondrial translation product, 1530 (Sept.)

Kidney
glomerulonephritis, membranous, chronic progressive demyelinating neuropathy associated with, 342 (Feb.)
nephrotoxicity, chronic, complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy, 147 (Jan.)

Lactic acid
cerebral delivery and uptake of, during and after ischemia, in the piglet, 1549 (Sept.)

Language
aphasia, acquired, in childhood, clinical and computed tomography investigations, 1165 (July)
aphasia, chronic, cerebellar glucose metabolism in, 1599 (Oct.)
aphasia, epilepsy and (Correspondence), 1571 (Sept.)
aphasia, global, without hemiparesis and (Correspondence), 1591 (Oct.)
aphasia, global, without hemiparesis, multiple etiologies, 201 (Feb.)
aphasia, nonfamilial dysphasic dementia, reduced somatostatin-like immunoreactivity in cerebral cortex in, 1448 (Sept.)
bulbar palsy, progressive, gangnopathy and (Correspondence), 1688 (Oct.)
dysarthria, acquired, in childhood, analysis of dysarthric features in relation to neurologic deficits, 296 (Feb.)
dysarthria, severe, with right hemisphere stroke, 1061 (June)
mispronunciation, hyperkinetic (Correspondence), 1568 (Sept.)
perseveration, behavioral neurology, 1798 (Nov.)
speech without conscious awareness after commissurotomy, 682 (Apr.)
uttering, assessment of, and acquired brain lesions (Correspondence), 1434 (Aug.)

Learning
Alzheimer's disease, probable, in patients with, 784 (May)

Leber's congenital amaurosis
cytosine, thymidine activity in leukocytes from patients with, enzyme characterization and activity levels, 1578 (Dec.)

Legionnaires' disease
brain abscess and, 333 (Feb.)

Leigh's disease
sleep studies and, automatic respiratory failure, case report, 1876 (Dec.)

Leukemia
acute monoblastic, in hematologic remission, infiltrative polyneuropathy due to, 474 (Mar.)
central nervous system, blast cells in (Correspondence), 1691 (Oct.)
central nervous system complications of a newly recognized subtype of, acute
myelonoarcotic with a pericentric inversion of chromosome 15, 659 (Apr.)

Leukodystrophy
hereditary adult-onset, adrenergic dysfunction in, 1421 (Aug.)

Leukodystrophy
hereditary adult-onset, adrenergic dysfunction in, 1421 (Aug.)

Levodopa
Parkinson's disease, combination bromocriptine treatment for, 5-year fol-
low-up, 826 (May)
Parkinson's disease, long-term aggravation of, nondopaminergic lesions and,
1559 (Sept.)
Parkinson's disease, methyl ester treatment of, 1242 (July)
Parkinson's disease, progression of, without, 695 (Apr.)
Parkinson's disease, 3-O-methyl-dopa and motor fluctuations in, 856 (May)
peripheral pharmacokinetics of, in untreated, stable, and fluctuating parkin-
sonian patients, 940 (June)

Levodopa/carbidopa: See also Carbidopa/levodopa
controlled-release of, Parkinson's disease, 233 (Feb.)
controlled-release, Sinemet CR4 treatment of response fluctuations in Par-
kinson's disease, 1607 (Oct.)

Lewy bodies
concentric hyaline inclusions in, enteric ganglion cells, Parkinson's disease and
meganeuro, 1253 (July)
Life-support techniques
respirators, ocularmotor function in patients in, amyotrophic lateral sclerosis
(Clinical/Scientific Note), 1431 (Aug.); correction, 1606 (Oct.)
Lipids
serum, stroke and, 507 (Mar.)
Lipofuscinosis
ceroid, computed tomography in, 1025 (June)
Lipoma
cerebellomeningeal angle, hereditary, hereditary, schwannomatosis due to,
case report, 337 (Feb.)
Lipoproteins
stroke, risk assessment for, in ischemic cerebrovascular disease, 513 (Mar.)
stroke, serum lipids and, after, 507 (Mar.)
Liver
hepatotoxicity, fatal, valproic acid, retrospective review, 379 (Mar.)
Lorazepam
epilepsy, childhood, and serial seizures, effectiveness and tachyphylaxis, 190
(Apr.)
hepatic encephalopathy, Fischer syndrome, 1563 (Sept.)
Lumbar radiculopathy
steroids for (Correspondence), 1689 (Sept.)
Lung cancer
small cell, delayed leukoencephalopathy in survivors with, 1198 (July)
Lupus erythematosus
systemic, cerebral blood flow in, with or without cerebral complications, 1596
(Oct.)
systemic, neuromuscular antibodies and cognitive function in, 484 (Mar.)

Lyme disease
Borrelia burgdorferi infection of the nervous system, chronic forms of, 1031
(June)
peripheral neuropathy, treatable, cause of, 1700 (Nov.)
Lymphocyte: See also Blood
cerebrospinal fluid subpopulations, neurosarcoidosis, 878 (May)
Lymphocytic adeno-hypophysitis
pituitary mass and, 158 (Jan.)
Lymphoma
B cell, of peripheral nerve, demyelinating neuropathy due to primary IgM
kappa, 1251 (July)
central nervous system, primary, computer-assisted stereotoxic biopsy for
the diagnosis of, 1190 (July)
non-Hodgkin's unilateral optic neuropathy in (Clinical/Scientific Note), 1563 (Sept.)
T helper cell, myasthenia gravis associated with, 1405 (Aug.)

Machado-Joseph disease
search for a physiologic marker of, 112 (Jan.)

Macroglubulinemia
peripheral neuropathy in, incidence and antigen-specificity of M proteins, 1506 (Sept.)
Magnetic resonance imaging (MRI)
brain tumor, in canine glioma, 1235 (July)
cerebral dominance, sex, and callosal size in, 1385 (Aug.)
corpus callosum atrophy and, 350 (Feb.)
corpus callosum, normal and abnormal morphology of, 1240 (July)
cranial, in the evaluation of myelopathy of undetermined etiology, 840 (May)
dementia diagnosis and, 540 (Mar.)
Guillain-Barré syndrome, Miller Fisher variant of (Clinical/Scientific Note), 1431 (Aug.)
herpes simplex encephalitis, early diagnosis of, 179 (Feb.)
multiple sclerosis, analysis of correlations to peripheral blood and spinal fluid
abnormalities in, 1527 (Sept.)
multiple sclerosis diagnosis and (Correspondence), 1566 (Sept.)
multiple sclerosis, diagnostic role of, in childhood, 689 (Apr.)
myelopathy, multiple sclerosis and (Correspondence), 1582 (Oct.)
stroke, sensitivity and specificity of, 1580 (Oct.)
vascular dementia, 29 (Jan.)

Malignant hyperthermia
adverse activities and, in Joseph disease and oligocentrocerebellar atrophy,
106 (Jan.)

Meador's disease
muscle energy metabolism in, in vivo phosphorus nuclear resonance
spectroscopy, 1720 (Nov.)
myo-adenylate deaminase deficiency and, observations in a combined enzyme
deficiency, 1039 (June)
two generations of, autosomal recessive transmission with manifesting het-
erozygote, 1568 (Sept.)

Medical education
Academy continuing medical education program reaccredited for 6 years,
27A (May)
American Board of Psychiatry and Neurology, review course guidelines
reaffirmed, 23A (Oct.)
Charcot, J.M. and ambulatory automatics (History of Neurology), 1084
(June)
expected requirements of neurologists (Letter), 174 (Jan.)
five medical schools receive neuroscience funding, 24A (Apr.)
future needs of neurology (Correspondence), 1568 (Sept.)
Johns Hopkins Medical Institutions, first US endowed chair in neuro-opht-
almology, 31A (June)
model clinical neurosciences curriculum, 1697 (Nov.)
neuroimaging, new Academy position statement on, 22A (Mar.)
neurology practice patterns in Colorado, 287 (Feb.)
neurology residence training programs in the United States, 820 (May)

Medicare
ANN joins coalition to change maximum allowable actual charges (MAACs),
25A (Sept.)
fee limits, "maximum allowable actual charges," 23A (Apr.)
over one-third of neurologists now accept assignment, 25A (Sept.)
physician payment provisions, 21A (Jan.)

Membranous glomerulonephritis
chronic progressive demyelinating neuropathy associated with, 342 (Feb.)

Memory
orders of recent, cognitive evoked potentials and, 526 (Mar.)
disturbances of, physostigmine improves electroconvulsive therapy (ECT)-
duced, 871 (May)
neurochemical dissociation of systems of, 789 (May)
remote, recurrent syndrome and, 522 (Mar.)

Meningoradiculoneuritis
tick-borne, clinical, electrophysiologic, and histologic findings in 10 cases, 749
(May)

Mental retardation
cardiovascular and, with autophagic vacuolar myopathy, 1065 (June)

Metabolism
altered striatal dopaminergic, 36 hours after unilateral trauma to the human
mesencephalon, 322 (Feb.)
amyotrophic lateral sclerosis, physiologic and metabolic response to pro-
gressive and prolonged exercise in, 1217 (July)
amyotrophic lateral sclerosis, reduction in insulin receptors in, correlates
with reduced insulin sensitivity, 1375 (Aug.)
cerebral glucose utilization, local, coupled forebrain increases of, and blood
flow during physiologic stimulation of a somatosensory pathway, in rat, 11
(Jan.)
glucose, cerebellar, in chronic aphasia, 1599 (Oct.)
glutaric aciduria type I, clinical heterogeneity and neuroradiologic features
of, 1604 (Oct.)
ischiatric infarction, acute, metabolic and clinical correlates of, 1103 (July)
ischiatric striatal injury, role of dopamine in, metabolic evidence, 1712 (Nov.)
Meador's disease, muscle energy metabolism in, in vivo phosphorus
nuclear magnetic resonance spectroscopy, 1720 (Nov.)
muscular dystrophy, Duchenne, phosphorus nuclear magnetic resonance
spectroscopy, age-related changes in, 165 (Jan.)
myotonic dystrophy, basal metabolic rate in, evidence against hypo-
metabolism, 1021 (June)
valproate, lactate/pyruvate interactions and (Correspondence), 1687 (Oct.)
3-O-methyl-dopa
motor fluctuations and, in Parkinson's disease, 856 (May)

Migraine headache
amaurosis fugax and thrombocytopenia (Correspondence), 1888 (Dec.)
anesia, transient global and, clinical characteristics and prognosis, 733
(May)

Miller Fisher syndrome
neuropathy in, clinical and electrophysiologic findings, 1493 (Sept.)

Mitochondrial encephalomyopathy
ataxia, sleep apnea and (Clinical/Scientific Note), 1429 (Aug.)
partial cytochrome c oxidase deficiency and, 58 (Jan.)

December 1987 NEUROLOGY 37 1903
Monoclonal paraproteinemia

Movement disorders

Multiple sclerosis

Muscle
spinal neurons, extracts of muscle biopsies from patients with spinal muscular atrophies inhibit neurite outgrowth from, 1361 (Aug.)
tibial, posterior, source of 'paradoxical lateralization' of cortical evoked potentials of distribution of, 82 (Jan.)
tibial, posterior, stimulation of, cervical synapse-dependent somatosensory evoked potential following, 1417 (Aug.)
trigeminal ganglion neurons, degeneration of, caused by retrograde axonal transport of doxorubicin, 985 (June)
trigeminal neuregia, comparison of t-baclofen and racemic baclofen in, 1725 (Nov.)
trigeminal neuregia, complete heart block and (Clinical/Scientific Note), 1089 (June)
trigeminal neuregia, neurophysiologic assessment of trigeminal function after surgery for, 631 (Apr.)
Neuroanatomy
fragments of neurologic history, Felix Vicq d'Azyr and (Historical Neurology), 1349 (Aug.)
Neurocytosterosis
plasma levels of praziquantel decrease when dexamethasone is given simul-
taneously (Clinical/Scientific Note), 1561 (Sept.)
Neurofibromatosis
nomenclature revised, 26A (Oct.)
paragangliomas, multiple, in, new neuroendocrine neoplasia, 129 (Jan.)
Neurology (journal)
change in letters to editor: now two classifications, 23A (Apr.)
Editorial Board role, editorial changes, 26A (July)
Rowland, Lewis P, tribute to, 1 (Jan.)
Neurophysiology
gatekeeper concept in health maintenance organizations, 22A (Dec.)
hospital lengths-of-stay by diagnosis related groups for neurologic patients, 139 (Jan.)
medicine at the end of life, 1079 (June)
model clinical neuroscience curriculum, 1697 (Dec.)
patterns of, in Colorado, 287 (Feb.)
residency training programs in the United States, 820 (May)
Neuroma
contralateral acoustic, hemifacial spasm due to, case report, 339 (Feb.)
Neuropathy
peripheral, chronic acquired demyelinating, somatosensory evoked poten-
tials in, 313 (Feb.)
Neurosarcoidosis
long-term clinical course of, 461 (Mar.)
lymphocyte subpopulations in cerebrospinal fluid, 878 (May)
Neurosarcoidosis
penicillin concentrations in serum and CSF during high-dose intravenous treatment for, 1214 (July)
Neurotoxic disease
recognition of, 276 (Feb.)
Neurol NewsLetter
AAEES announces deadline for examination, 26A (Oct.)
AAN Sections open to all members, 22A (Mar.)
ABPN reaffirms guidelines for review courses, 23A (Oct.)
Academy announces Research Fellowship Awards, 22A (Mar.)
Academy CME reaccredited for 6 years, 27A (May)
Academy position on neurologic rehabilitation, 22A (Mar.)
Academy signs 4-year agreement with HBJ, 27A (Mar.)
AEFGS announces election results, 26A (Apr.)
AMA booklet on physician DRGs, 26A (Apr.)
AMA to host reception for residents, 21A (Feb.)
American Board of Clinical Neurophysiology certification, 27A, (Dec.)
American Board of Clinical Neurophysiology, Inc. certifications, 27A (Mar.)
American Board of Clinical Neurophysiology, Inc., 26A (July)
American EEG Society statement on clinical use of quantitative EEG, 27A (May)
American Epilepsy Society announcements, 28A (Mar.)
American Epilepsy Society annual meeting and courses, 22A (Aug.)
Announcement of a clinical trial for treatment of parkinsonism, 22A (Aug.)
Applications sought for senior and postdoctoral research associateships, 27A, (Dec.)
ASIM opposes the release of HCFA's hospital-specific mortality data, 25A (Nov.)
At AAN Annual Meeting, 27A (Mar.)
Kevin Barron named Srinivasan Lecturer, 26A (Nov.)
Blepharospasm symposium, 32A (June)
Board examination application deadline, 26A (July)
Board examination application deadline, 26A (May)
Brady named Academy's Associate Executive Director, 31A (June)
Call for nominations underway for Potamkin Prize, 22A (Aug.)
Call for proposals to study stroke in blacks and other minorities, 29A (July)
Changes announced by American Board of Clinical Neurophysiology, Inc., 27A (Oct.)
CJD associated with human dura graft reported, 26A (Apr.)
Clinical research fellowship: Neural grafting in Parkinson's disease, 26A (Oct.)
Robert C. Collins appointed chairman at UCLA, 23A (Oct.)
Combined rehabilitation conference, 32A (June)
Concern over current autopsy rate, 22A (Jan.)
Conference on MS management to be held, 23A, (Dec.)
Course for public office candidates, 25A (Apr.)
Antonio R. Damasio appointed chairman at Iowa, 21A (Jan.)
David Drachman named to panel, 26A (Apr.)
Decline in reported SSBP cases, 22A (Jan.)
Department appointments are announced, 21A (Feb.)
Dizziness is subject of new pamphlet, 23A (Feb.)
Dramatic growth, expanded educational programs, and needs assessment are hallmarks of AAN's progress, 26A (June)
Electroencephalographers elect officers, set meetings, 23A (Jan.
Executive Board Meetings, 28A (June)
Dr. Ruggero Fariello named neurological sciences chairman at Rush, 24A (Nov.)
Fight For Sight Awards Program, 1988, 26A (Oct.)
Final congressional action, 21A (Jan.)
Five major medical schools to receive neuroscience funding, 24A (Apr.)
Dr. Foley receives award as distinguished woman in medicine, 31A (June)
Fortune Magazine on HMOs, 22A (Dec.)
From the President, 25A (July)
From the President, 21A (Dec.)
From Washington: AAN joins coalition to change MAACs, 25A (Sept.)
From Washington: Congress ready to reduce budget, 25A (Sept.)
From Washington: More than one-third of neurologists are now accepting Medicare assignment, 25A (Sept.)
Funds available for narcolepsy research, 28A (Mar.)
Dr. Joseph Green is appointed to VA post, 25A (Sept.)
Robert C. Griggs is new Chairman at Rochester, 21A (Jan.)
Robert C. Griggs, MD—G. Milton Shy Visiting Professorship, 31A (June)
Donald Harter goes to Howard Hughes Medical Institute, 23A (Oct.)
HCFA administrator emphasizes his concerns with quality, 21A (Feb.)
Hopkins sets chair in neuro-ophthalmology, 31A (June)
Hospital peer review gets strong boost from Justice Department, 22A (Feb.)
Joint Commission adopts new name, 29A (Nov.)
Joint Parkinson's disease symposia announced, 24A (Jan.)
Robert Katzman nominated to represent neurologists on Alzheimer's disease advisory panel, 27A (Mar.)
Koller is new chairman at Kansas, 30A (June)
J. William Langston receives award, 24A (Apr.)
McQuillen named chairman at Kentucky, 27A (May)
Medicare assignment, 23A (Apr.)
Message from the Editor-in-Chief, 23A (Apr.)
Message from the Editor-in-Chief, 26A (July)
Michael Prize 1987/88, 26A (Apr.)
G.F. Molinari is Academy representative at uniform emergency medical abstract meeting, 27A (Mar.)
Movement disorder meeting—call for abstracts, 32A (June)
MRI conference to be held, 38A (July)
National Advisory Council adds new members, 26A (July)
National smell survey results made available by National Geographic, 27A, (Dec.)
New Academy policy on neuroimaging training, 22A (Mar.)
New diplomas, American Board of Electroencephalography and Neu-opathology, 23A (Jan.)
New Diplomates of the American Board of Psychiatry and Neurology, Inc., 26A (Sept.)
New diplomats of the American Board of Psychiatry and Neurology, Inc., 27A (Apr.)
New Diplomates of the American Board of Psychiatry and Neurology, Inc., 26A (May)
News from the American Association of Electromyography and Electrodiagnosis, 23A (Jan.)
NHI funding reinstated, 23A (Apr.)
NINCDS announces multicenter carotid endarterectomy study, 25A (Nov.)
NINCDS deputy director named to NIH extramural post, 38A (July)
NINCHS names 10 more Katrina Investigators, 28A (Mar.)
NINCDS seeks proposals to study neurologic aspects of low back pain, 28A (July)
Nomenclature revised on neurofibromatosis, 26A (Oct.)
Dr. Pestronk receives Lawrence C. McHenry Award, 26A (July)
Pfizer announces $50,000 award for innovation, 26A (July)
Physician input causes Administration to shift gears on DRGs in '88 budget, 22A (Feb.)
Pincus appointed neuropathology chairman, 23A (Mar.)
Potamkin Prize announced, 25A (July)
President-elect of ANA named, 21A (Jan.)
President's report: AAN making strides in legislative arena, 22A (Nov.)
President's report, 27A (May)
Proposals sought to study diabetic neuropathy, tuberous sclerosis, Batten's disease, 23A (Feb.)
Queen Square alumni association under consideration, 32A (June)
Queen Square alumni gathering announced, 24A (Jan.)
Reagan budget draws heat, 23A (July)
Record number of abstracts submitted for annual meeting, 21A (Feb.)
Registry of Fahn's disease, 28A (July)
Rehabilitation Institute of Chicago announces appointment, 24A (Jan.)
Russell N. De Jong Society meeting, 28A (July)
Dr. Bruce S. Schoenberg dies, 25A (Sept.)
Second course in Spanish held, 22A (Feb.)
Dr. William Shapiro named chairman at Memorial Sloan-Kettering Cancer Center, 24A (Nov.)
Tourrette Syndrome Association research and training grants available, 27A, (Dec.)
Rep. H. Waxman discusses 100th Congress with AAN leaders, 30A (June)
S.G. Waxman appointed chairman at Yale, 23A (Mar.)
Henry deF. Webster heads International Neuropathology Society, 21A (Feb.)
16th Princeton Conference is scheduled, 22A (Oct.)
1986-1987 Annual Report of the American Board of Psychiatry and Neurology, Inc., 22A (Aug.)
Nicardipine potential beneficial effect of, in rat model of transient forebrain ischemia, 809 (May)
Nicotine central nervous system and (Correspondence), 1887 (Dec.)
NINDS National Advisory Council adds four new members, 26A (July)
Norepinephrine Parkinson's disease and dementia, dopamine and, in locus ceruleus, 42 (Jan.)
Nuclear magnetic resonance spectroscopy (NMR) bioenergetic heterogeneity of human mitochondrial myopathies, 257 (Feb.)
Duchenne muscular dystrophy, age-related metabolic changes, 165 (Jan.)
McArdle's disease, muscle energy metabolism in, 1720 (Nov.)
muscular enzyme deficiencies involving glycogenolysis and glycolysis study, 165 (Jan.)
neonatal brain, use of chemical shift of phosphomonoester P-31, for determination of intracellular pH in, 1771 (Nov.)
Nuclear magnetic resonance imaging: See Magnetic resonance imaging
Numb cheek syndrome Roger's sign (Letter), 257 (Feb.)
thermography for (Letter), 356 (Feb.)
Nutrition myotonia congenita, acetazolamide-responsive, 488 (Mar.)
Nystagmus: See also Eye paroxysmal spontaneous, vertigo and, evoked by lateral eye position, 1553 (Sept.)
Obesity morbid, neurologic complications after gastric resection surgery for, 196 (Feb.)
Obituary Bruce S. Schoenberg, 25A (Sept.)
John Seerson, 1152 (July)
Obstructive sleep apnea syndrome bimodality electrophysiologic evaluation of brainstem in, 1036 (June)
Oligoclonal IgG in tears, 853 (May)
Oligosaccharides urinary, Sandhoff's disease, adult, ganglioside storage, hexosaminidase deficiency and, in, 75 (Jan.)
Olivopontocerebellar atrophy glutamate and malate dehydrogenase activities in Joseph disease and, 106 (Jan.)
glutamate dehydrogenase in (Correspondence), 1687 (Oct.)
skeletal myoclonus in, treatment with trihexyphenidyl, 1258 (July)
Olszewski, Jerry
brain stem reticular formation, cartographer of (Historical Neurology), 1881 (Dec.)
Ophthalmic infantile herpes zoster, acute hemiparesis and, following intrauterine chickenpox, 1557 (Sept.)
Ophthalmoplegia steroid-responsive painful, not always sign of Tolosa-Hunt syndrome (Letter), 544 (Mar.)
Oxytocin Alzheimer's disease, postmortem brain levels of, 1001 (June)
Pain diabetic neuropathy, amitriptyline relieves, in patients with normal or depressed mood, 589 (Apr.)
lumbar radiculopathy, steroids for (Correspondence), 1689 (Oct.)
Palsy abducens nerve palsies, delayed, associated with cervical spine fractures (Clinical/Scientific Note), 1565 (Sept.)
Bell's, familial recurrent, with ocular motor palsies, 1369 (Aug.)
facial, upper motor neuron, reconsidered, organization of the facial nucleus and corticofacial projection, in monkey, 930 (June)
progressive bulbar, gammopathy and (Correspondence), 1688 (Oct.)
progressive supranuclear, and a multi-infarct state, 576 (Apr.)
progressive supranuclear, limb dystonia in, 1546 (Sept.)
progressive supranuclear palsy, multi-infarct (Correspondence), 1819 (Nov.)
progressive supranuclear, reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease and, 906 (June)
Paradoxical lateralization source of, of cortical evoked potentials to posterior tibial nerve stimulation, 812 (Jan.)
Paralysis meningovascular encephalitis, tick-bite, clinical, electrophysiologic, and histologic findings in 10 cases, 749 (May)
Paramnesia delayed reduplicative, 701 (Apr.)
Paraparesis tropical spastic, Seychelles Islands, clinical and case-control neuroepidemiologic study, 1322 (Aug.)
Paraplegia familial spastic, "pure", autosomal dominant form of, clinical findings and linkage analysis of a large pedigree, 916 (June)
Paraproteinemia monoclonal, with subacute encephalopathy, seizures, and scleromyxedema, 1054 (June)
motor neuron disease and, 335 (Feb.)
Parquet Parkinson's disease and (Correspondence), 1820 (Nov.)
Parkinson's disease and (Correspondence), 1278 (Apr.)
Parathyroid hormone hyperparathyroidism, idiopathic, extensive brain calcification with, and persistent neurologic dysfunction, 307 (Feb.)
Parkinson's disease acquired, evidence from a geographic comparison with multiple sclerosis, 467 (Mar.)
avanced, use of partial dopamine agonist, ciladopa, 863 (May)
animal models of, terguride, mixed dopamine agonist-antagonist in, 723 (Apr.)
apomorphine, diurnal responsiveness to, 1250 (July)
dementia and, norepinephrine and dopamine in locus ceruleus, 42 (Jan.)
dopaminergic mechanisms in hemiparkinsonian monkeys, 1962 (Oct.)
dystonia, forms of, in patients with, 1069 (June)
hemiparkinsonism, neuropsychological disturbances in, 1762 (Nov.)
idiopathic, akathisia in, 477 (Mar.)
idiopathic, case-control study of smoking habits, dementia, and other illnesses in, 226 (Feb.)
levodopa methyl ester treatment of, 1242 (July)
levodopa, peripheral pharmacokinetics of, in untreated, stable, and fluctuating parkinsonian patients, 940 (June)
levodopa/carbidopa (Sinemet), controlled-release (Correspondence), 1567 (Sept.)
levodopa/carbidopa, controlled-release, Sinemet CR4 treatment of response fluctuations in, 1607 (Oct.)
long-term aggravation of, nondopaminergic lesions and, 1539 (Sept.)
Maladie de Parkinson unilateral, symptomatic of a one tumor of pons et de la cervelet (Heterocerebral Neurology), 1145 (July)
megacolon and, concentric hyaline inclusions (Lewy bodies) in enteric ganglia, 1253 (Dec.)
motor fluctuations and 3-0-methyldopa in, 856 (May)
myasthenia gravis and, adverse effect of trihexyphenidyl on neuromuscular transmission, 832 (May)
nuclear magnetic resonance imaging, cerebral cortex and, in Alzheimer's disease and, 1054 (June)
neuronal and clinical features of, in Alzheimer's disease patients, 154 (May)
onoral face motor control impairment in, 394 (Mar.)
paraparesis and (Correspondence), 1820 (Nov.)
paraplegia and (Correspondence), 728 (Apr.)
pharmacology, controlled-release levodopa/carbidopa in, 233 (Feb.)
postprandial and orthostatic hypotension in, 356 (Mar.)
pregnancy and, 1245 (July)
progression of, in the Republic of San Marino, 1679 (Oct.)
progressive supranuclear palsy, multi-infant (Correspondence), 1819 (Nov.)
prolactin response in (Correspondence), 729 (Apr.)
reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in, and Alzheimer’s disease, and progressive supranuclear palsy, 905 (June)
seizure and motor problems in arms and hands, 951 (June)
smooth pursuit during dose-related on-off fluctuations in, 1389 (Aug.)
spatial disorientation as an early symptom of, 480 (Mar.)
tremor, caffeine and, 169 (Jan.)

Pediatric neurology
aphasia, acquired, in childhood, clinical and computed tomography investigations, 1165 (July)
ataxia, infantile X-linked, deafness and, new clinicopathologic entity, 1344 (Aug.)
brain death, guidelines for the determination of, in children, 1077 (June)
cerebral infarct, computed tomography in, 1025 (June)
dysarthria, acquired, in childhood, analysis of dysarthric features in relation to neurologic deficits, 296 (Feb.)
encephalomyopathy, mitochondrial, heterogeneous phenotypes of, in a single kindred, 1967 (Dec.)
epilepsy, complex partial, phenacemide therapy of, in children, determination of plasma drug concentrations, 1861 (Dec.)
epilepsy, lorazepam in (Correspondence), 1569 (Sept.)
herpes zoster ophthalmicus, infantile, acute hemiparesis and, following intravenous chickenpox, 1537 (Sept.)
multiple sclerosis, nuclear magnetic resonance imaging, role of, in the diagnosis of, in childhood, 689 (Apr.)
myasthenia, familial infantile, synaptic vesicle abnormality in, 206 (Feb.)
premature infant, positive rolandic sharp waves in the EEG of, 1481 (Sept.)
seizures, complex partial, in children, ictal manifestations and their relation to clinical course, 1379 (Aug.)
seizures, first seizure and first recurrence similarity, in children (Clinical/Scientific Note), 1429 (Aug.)
seizures, neonatal, characterization and classification of, 1837 (Dec.)
status epilepticus and serial seizures, lorazepam in, effectiveness and tachyphylaxis, 190 (Feb.)

Peer review
hospital, Justice Department supports, 22A (Feb.)

Penicillin
congenital, in serum and CSF during high-dose intravenous treatment for neurosyphilis, 1214 (July)

Penicillin
epilepsy, refractory status epilepticus treatment, 500 (Mar.)

Peripheral nervous system
myelopathy, combined central and peripheral, 1287 (Aug.)
Perseveration
behavioral neurology, 1736 (Nov.)

Pertussis vaccine
lethal reaction to, treatment with histamine H1 antagonists, 1068 (June)
Pesticide
carbamate, delayed neurotoxicity after ingestion of, 1229 (July)

Pharmacology
adenosine, intravenous, selectively increases blood flow to xenotransplanted intracerebral gliomas, 1870 (Dec.)
Alzheimer’s disease, absence of neurophysiologic effect of lecithin in, by EEG topography, 1016 (June)
amyotrophic lateral sclerosis, brain glutamate deficiency in, 1845 (Dec.)
anticholinergics, sustained-release, in dystonia (Clinical/Scientific Note), 885 (May)
anticonvulsant drugs, effect of, on glutamate neurotoxicity in cortical cell culture, 319 (Feb.)
antifibrinolytic therapy, predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage, influences of clinical condition, CT results, and antifibrinolytic therapy, 1586 (Oct.)
barbiturate abuse, nonconvulsive status epilepticus and (Correspondence), 1258 (July)
cyclosporin A toxicity, cerebral blindness and encephalopathy with, 1072 (July)
cyclosporine, chronic nephrotoxicity complicating treatment of chronic inflammatory demyelinating polyradiculoneuropathy, 147 (Jan.)
diabetic neuropathy pain, amitriptyline relieves, in patients with normal or depressed mood, 589 (Apr.)
doxorubicin, degeneration of trigeminal ganglion neurons caused by retrograde axonal transport of, in mouse, 985 (June)
epilepsy, allopurinol and (Correspondence), 1691 (Oct.)
epilepsy, antiepileptic drugs, causes of treatment failure with, over time, 1620 (Oct.)
epilepsy, childhood, lorazepam and, effectiveness and tachyphylaxis, 190 (Feb.)
epilepsy, childhood, lorazepam in (Correspondence), 1569 (Sept.)
epilepsy, complex partial, in children, phenacemide therapy of, determination of plasma drug concentrations, 1861 (Dec.)
epilepsy, effect of psychotropic medications on seizure control in patients with, 1525 (Sept.)
growth hormone, pituitary, iatrogenic Creutzfeldt-Jakob disease and, 1520 (Sept.)
Huntington’s disease, benzodiazepine receptor complexes in frontal cerebral cortex, increased number and altered regulation of, 916 (June)
thymus, medullary, steroids for (Correspondence), 1860 (Oct.)
memory disturbances, electroconvulsive therapy-induced, physostigmine improves, 871 (May)
memory systems, neurochemical dissociation of, scopolamine, 789 (May)
multiple sclerosis, evoked potentials predict clinical changes in, drug study, 1754 (Nov.)
multiple sclerosis, indomethacin, interferons and (Correspondence), 888 (May)
ymastocytosis, quantitative correlation between plasma pyridostigmine levels and neuromuscular function in, 900 (May)
yellow, essential, anticholinergic-responsive, physiologic and pharmacologic study in, 608 (Apr.)
yetioma congenita, acetazolamide-responsive, 488 (Mar.)
nicotina, neglect, dopamine agonist therapy for, in humans, 1705 (Nov.)
neurophysiology, penicillin concentrations in serum and CSF during high-dose intravenous treatment for, 1214 (July)
nicardipine, potential beneficial effect of, in rat model of transient forebrain ischemia, 809 (May)
olvopontocerebellar atrophy, skeletal myoclonus in, treatment with trihexyphenidyl, 1258 (July)

Parkinson’s disease, advanced, use of partial dopamine agonist, ciladopa, 863 (May)
Parkinson’s disease, animal models of, terguride, mixed dopamine agonist-antagonist, 723 (Apr.)
Parkinson’s disease, anorexia, diurnal responsiveness to, 1250 (July)
Parkinson’s disease, bromocriptine and levodopa combination treatment, 5-year follow-up, 826 (May)
Parkinson’s disease, controlled-release levodopa/carbidopa in, 233 (Feb.)
Parkinson’s disease, fluctuations in plasma dopamine level impair memory in, 1371 (Aug.)
Parkinson’s disease, levodopa methyl ester treatment of, 1242 (July)
Parkinson’s disease, levodopa, peripheral pharmacokinetics of, in untreated, stable, and fluctuating patients with, 940 (June)
Parkinson’s disease, levodopa/carbidopa, controlled-release, Sinemet CR treatment of response fluctuations in, 1607 (Oct.)
Parkinson’s disease, long-term aggravation of, non dopaminergic lesions and, 1539 (Sept.)
Parkinson’s disease, motor fluctuations and, long-acting carbidopa/levodopa (CR-4-Sinemet), 870 (May)
Parkinson’s disease, progression of, without levodopa, 695 (Apr.)
Parkinson’s disease, prolactin response in (Correspondence), 729 (Apr.)
Parkinson’s disease, smooth pursuit during dose-related on-off fluctuations in, 1389 (Aug.)
Parkinson’s disease, 3-O-methylpyridine and motor fluctuations in, 856 (May)
perutis vaccine reaction, lethal, treatment of, with histamine H1 antagonists, 1068 (June)
phencyclidine toxicity, responsive to dantrolene, 865 (May)
phenylpropanolamine, intracerebral hemorrhage and, 399 (Mar.)
phenelzine toxicity, responsive to dantrolene, 865 (May)

Phenylpropanolamine, intracranial hemorrhage and, 399 (Mar.)
phenolamine, from human cadavers, neurologic disease in ten recipients, 1211 (July)
plausibleness, plasma levels of, decrease when dexamethasone is given simultaneously (Clinical/Scientific Note), 1561 (Sept.)
prognadone, controlled study of, in partial seizures, methodology and results, 1729 (Nov.)
pyridoxine overdose, acute sensory neuropathy-neuropathy from, 1729 (Nov.)
P3 event-related potentials, cholinergic modulation of, in humans, 146 (Feb.)
refractory status epilepticus, pentobarbital treatment of, 500 (Mar.)
restless legs syndrome, opiates in controlling symptoms of (Correspondence), 1884 (Dec.)
Ross River virus polyomysitis, experimental, interferon treatment of, 1189 (July)
seizure therapy, progesterone (Correspondence), 1433 (Aug.)
seizures, first seizure and first recurrence similarity, in children (Clinical/Scientific Note), 1429 (Aug.)
seizures, phenytoin and carbamazepine, alone and in combination, anticonvulsant and neurotoxic effects, 1111 (July)
seizures, refractory complex partial, vigabatrin for, multicenter single-blind study with long-term follow-up, 184 (Feb.)
Sinemet, controlled-release (Correspondence), 1567 (Sept.)
subsutal scarring penanecephalitis, intraventricular alpha 2b interferon for (Clinical/Scientific Note), 1884 (Dec.)
thyrotropin-releasing hormone, intrathecal, pharmacokinetics of, 597 (Apr.)
tremor, kinetic predominant essential, successful treatment with clonazepam, 471 (Mar.)
trigeminal neuralgia, comparison of L-baclofen and racemic baclofen in, 1725 (Nov.)
trihexyphenidyl, adverse effect of, on neuromuscular transmission, Parkinson's disease and myasthenia gravis, 802 (May)
valproate, lactate/pyruvate interactions (Correspondence), 1687 (Oct.)
valproate toxicity, clinical, induced by acetylsalicylic acid, 1392 (Aug.)
valproic acid, fatal hepatotoxicity, retrospective review, 379 (Mar.)
valproic acid, hepatotoxicity of, transitional polytherapy, liver enzymes and (Correspondence), 1592 (Oct.)
valproic acid, substitution of Depakene (Abbott) with generic product, responsive to dantrolene, 865 (May)
voice tremor, clonazepam and propranolol helpful in, 117 (Jan.)
yohimbine, oral, in human autonomic failure, 215 (Feb.)

Phenacemide
epilepsy, complex partial, in children, therapy of, determination of plasma drug concentrations, 1881 (Dec.)

Phenelzine
toxicity of, responsive to dantrolene, 865 (May)

Phenylketonuria (PKU)
dihydrobiopterin synthesis defect, adult with diurnal fluctuation of symptoms, 519 (Mar.)

Phenylpropanolamine
intracerebral hemorrhage and, 399 (Mar.)
intracranial hemorrhage, postpartum, and (Clinical/Scientific Note), 1866 (Oct.); correction, 1890 (Dec.)

Phenytoin
brainstem auditory evoked potentials and (Correspondence), 1687 (Oct.)
carbamazepine and, alone and in combination, anticonvulsant and neurotoxic effects, 1111 (July)
effect of intoxication of, on BAEPs (Correspondence), 1268 (July)

Phosphorylase deficiency
hyperuricemia in type V glycogenosis (Correspondence), 728 (Apr.)

Physostigmine
electroconvulsive therapy (ECT)-induced memory disturbances and, 871 (May)
myoclonus induced by, in Alzheimer's disease, 345 (Feb.)

Pick's disease
magnetic resonance imaging in the diagnosis of, 540 (Mar.)
posterior commissure imaging and histopathology in, 439 (Mar.)

Pituitary growth hormone
human cadavers, neurologic disease in ten recipients, 1211 (July)

Pituitary mass
lymphocytic adenohypophysisis causing, 158 (Jan.)

Plasma exchange therapy
Guillain-Barré syndrome, quantitative measurement, 837 (May)

Plasma membrane
are hypercontracted muscle fibers artifacts and do they cause rupture of?, 1466 (Sept.)

Pleocytosis
OKT-8+, cytomegalovirus encephalitis associated with episodic neurologic deficits and, 149 (Jan.)

Polyomavirus
virus, experimental, Ross River, interferon treatment of, 1189 (July)

Polynuropathy: See Nerve

Polyradiculoneuropathy: See also Nerve
chronic inflammatory demyelinating, chronic nephrotoxicity complicating cyclosporine treatment of, 147 (Jan.)

Position sense
ankle, quantitative assessment of, functional approach, 89 (Jan.)

Positonal vertigo: See Vertigo

Positron emission tomography (PET)
DNA polymorphisms and, for preclinical detection of Huntington's disease, 1441 (Sept.)
glucose utilization rate versus brain size, in humans, 583 (Apr.)
ischemic infarction, acute, metabolic and clinical correlates of, 1103 (July)
Pick's disease, and histopathology in, 439 (Mar.)
somatic sensory activation, human task-specific, 1301 (Aug.)
Wilson's disease, and 2-deoxy-2-[18F]fluoro-d-glucose studies of, 1707 (Nov.)

Pragmante
plasma levels of, decrease when dexamethasone is given simultaneously, 1561 (Sept.)

Preeclampsia: See also Trizahnertin
isolation of variant, diagnosis of familial amyloidotic polyneuropathy, 708 (Apr.)

Pregnancy
herpes simplex encephalitis in third trimester of pregnancy, successful outcome for mother and child, 1534 (Sept.)
intracranial hemorrhage, postpartum, phenytoinpropanolamine use and (Clinical/Scientific Note), 1686 (Oct.); correction, 1890 (Dec.)
intrauterine chickenpox, infantile herpes zoster ophthalmicus and acute hemiparesis following, 1557 (Sept.)
Parkinson's disease and, 1245 (July)

Progressive
partial seizures, controlled study of, methodology and results, 963 (June)
Progestosterone
seizure therapy (Correspondence), 1433 (Aug.)
Progressive supranuclear palsy
limb dystonia in, 1546 (Sept.)
multi-infarct state and, 570 (Apr.)

Prolactin
effect of electrical stimulation of medial temporal lobe structures in epileptic patients upon, and ACTH and growth hormone, 299 (Feb.)
response time of, in Parkinson's disease (Correspondence), 729 (Apr.)
serum, in the diagnosis of epilepsy, sensitivity, specificity, and predictive value, 1224 (July)

Propranolol
voice tremor, dysregulation of voluntary expiratory muscles, 117 (Jan.)

Prostaglandin E synthesis
multiple sclerosis and (Correspondence), 1437 (Aug.)

Protanopia
bulbospinal muscular atrophy and, pedigree with, 1019 (June)

Psychiatric
bradyphrenia, Parkinson's disease and, clinical and biochemical correlates of, 1130 (July); correction, 1693 (Oct.)
electroconvulsive therapy (ECT)-induced memory disturbances, physostigmine and, 871 (May)
Parkinson's disease, hemiparkinsonism, neuropathologic disturbances in, 1762 (Nov.)
phosphorylase deficiency, responsive to dantrolene, 865 (May)
psychotropic medications, effect of, on seizure control in patients with epilepsy, 1026 (Sept.)

Psychotropic medication
effect of, on seizure control in patients with epilepsy, 1525 (Sept.)

Pott's
bilateral cerebral, 1043 (June)

Pyridostigmine
quantitative correlation between plasma levels of, and neuromuscular function in myasthenia gravis, 800 (May)
overdose of, neuropsychopathology, acute sensory, from, 1729 (Nov.)

Pyruvate kinase
Duchenne and Becker dystrophy, creatine kinase, genetic linkage and, for carrier detection in, 4 (Jan.)

Quadruplegia
autonomic dystreflexia, orthostatic hypotension-induced, 1221 (July)

Rabies vaccine
Simplex-type, neurologic complications of, clinical and immunologic studies, 550 (Apr.)

Radiculopathy
cervical root stimulation in the diagnosis of, 329 (Feb.)
lumbar, steroids for (Correspondence), 1698 (Oct.)

Radiography
amnesia, transient global (Correspondence), 1889 (Dec.)
angiography, spinal cord, vascular malformations of, intrathecal perimedullary arterial fistulas fed by medullary arteries, 395 (June)
brain, milary metastases to, clinical and radiologic features (Clinical/Scientific Note), 1507 (Nov.)
cerebral ischemia, unilateral, angiographic comparison of carotid arteries in, 1027 (June)
cerebrocerebellar xanthomatosis, diagnosis and treatment of (Correspondence), 1091 (June)
computed tomography, cerebral ischemia, predicting of, after aneurysmal subarachnoid hemorrhage, influences of clinical condition, CT results, and antifibrinolytic therapy, 1586 (Oct.)
computed tomography, cerebral lipofuscinosis, 1025 (June)
computed tomography, quantitative analysis of brain morphometry in adult Down's syndrome at different ages, 1424 (Aug.)
contrast agents, iodinated, in myasthenia gravis, 1400 (Aug.)
corpus callosum, normal and abnormal morphology of, 1249 (July)
dementia, magnetic resonance imaging and the diagnosis of, 540 (Mar.)
education, neuroimaging training, 22A (Mar.)
herpes simplex encephalitis, early diagnosis of, by magnetic resonance imaging, 179 (Feb.)
magnetic resonance imaging, after corpus callosum, 350 (Feb.)
magnetic resonance imaging, brain tumor, in canine glioma, 1235 (July)

December 1987 NEUROLOGY 37 1909
magnetic resonance imaging, cerebral dominance, sex, and callosal size in, 1385 (Aug.)
magnetic resonance imaging, cranial, in the evaluation of myelopathy of undetermined etiology, 840 (May)
magnetic resonance imaging, Guillain-Barré syndrome, Miller Fisher variant of (Clinical/Scientific Note), 1431 (Aug.)
magnetic resonance imaging, multiple sclerosis, analysis of correlations to peripheral blood and spinal fluid abnormalities in, 1527 (Sept.)
magnetic resonance imaging, multiple sclerosis diagnosis and (Correspondence), 1586 (Sept.)
magnetic resonance imaging, myelopathy, multiple sclerosis and (Correspondence), 1892 (Oct.)
magnetic resonance imaging, stroke, sensitivity and specificity of, 1580 (Oct.)
magnetic resonance imaging, vascular dementia, 29 (Jan.)
multiple sclerosis, nuclear magnetic resonance imaging, role of, in the diagnosis of, in childhood, 689 (Apr.)
positron emission tomography, acute ischemic infarction, metabolic and clinical correlates of, 1103 (July)
positron emission tomography, DNA polymorphisms and, for preclinical detection of Huntington’s disease, 1441 (Sept.)
positron emission tomography, glucose utilization rate versus brain size, in humans, 583 (Apr.)
positron emission tomography, Pick’s disease, and histopathology in, 439 (Mar.)
quantitative autoradiographic study, Alzheimer’s disease, cortical GABA<sub>B</sub> and GABA<sub>B</sub><sub>2</sub> receptors in, 1454 (Sept.)
somatosensory activation, human task-specific, positron emission tomography, 1301 (Aug.)
systemic lupus erythematosus, cerebral blood flow in, with or without cerebrovascular complications, 1506 (Oct.)
transcranial Doppler, in brain death, 1733 (Nov.)
somatosensory activation, human task-specific, positron emission tomography, 1301 (Aug.)

Reductive paramnesia
delayed, 701 (Apr.)

Reflex
hyperactive vestibulo-ocular, in cerebellar degeneration, pathogenesis and treatment, 53 (Jan.)
trigeminal neuralgia, neurophysiologic assessment of trigeminal function after surgery for, 831 (Apr.)

Rehabilitation
American Academy of Neurology position on, 22A (Mar.)
respiratory failure, in progressive neuromuscular disease, role of intermittent negative pressure ventilation in treatment of, 1874 (Dec.)

Repeater F waves
carpal tunnel syndrome, comparison of sensitivity with sensory antidromic wrist-to-palm latency and distal motor latency in the diagnosis of, 773 (May)

Respiration
automatic respiratory failure, sleep studies and Leigh’s disease, case report, 1876 (Dec.)
respiratory failure, in progressive neuromuscular disease, role of intermittent negative pressure ventilation in treatment of, 1744 (Dec.)

Restless legs syndrome
opiates in controlling symptoms of (Correspondence), 1436 (Aug.)

Reye’s syndrome
hyperammonemia, effect of, on carnitine levels, in mice, 804 (May)

Ribonucleic acid (RNA)
neuronal, in situ analysis of, and chromatin, in Alzheimer’s disease, 309 (Feb.)

Roger’s sign
numb cheek syndrome (Letter), 357 (Feb.)

Rose River virus polyomatisis
experimental, interferon treatment of, 1189 (July)

S

Sandhoff’s disease
adult, ganglioside storage, hexosaminidase b-lability, and urinary oligosaccharides in, 75 (Jan.)

Sarcoidosis
neurosarcoidosis, cerebral spinal fluid lymphocyte subpopulations, 878 (May)
neurosarcoidosis, long-term clinical course of, 461 (Mar.)

Schindler, Heinrich Bruno
neurosyphilis description of (Classics in Neurology), 146 (Jan.)

Schoenberg, Bruce S
obituary, 25A (Sept.)

Schwannoma
ultrasonic diagnosis of (Clinical/Scientific Note), 1817 (Nov.)

Scleromyxedema
monoclonal paraproteinemias with subacute encephalopathy, seizures and, 1054 (June)

Scopolamine
memory systems, neurochemical dissociation of, 789 (May)

Scrapie infection
brain prion proteins during, changes in the localization of, 1271 (Aug.); correction, 1770 (Nov.)

Segerson, John
in memoriam, 1192 (July)

Seizures
absence epilepsies, concepts of, discrete syndromes or biological continuum? 993 (June)
absence, risk factors for, population-based case-control study in Rochester, Minnesota, 1308 (Aug.)
antiepileptic drugs, causes of treatment failure with, over time, 1620 (Oct.)
automobile accident risk, relation to seizure type, 1613 (Oct.)
breakthrough, following substitution of Depakene capsules (Abbott) with generic valproic acid (Clinical/Scientific Note), 1885 (Dec.)
childhood, lorazepam in (Correspondence), 1569 (Sept.)
complex partial, in children, ictal manifestations and their relation to clinical course, 1379 (Aug.)
complex partial, refractory, vigabatrin for, multicenter single-blind study with long-term follow-up, 184 (Feb.)
epilepsy, diagnosis of, serum prolactins in, sensitivity, specificity, and predictive value, 1224 (July)
first seizure and first recurrence similarity, in children (Clinical/Scientific Note), 1429 (Aug.)
generalized tonic-clonic, risk factors for, population-based case-control study in Rochester, Minnesota, 1315 (Aug.)
head and eye turning in, significance of, 1617 (Oct.)
head turning during, significance of direction in (Correspondence), 1092 (June)
intractable complex partial, the “initial motionless stare” and surgical outcome following temporal lobectomy, 1255 (July)
mesial frontal lobe, epileptic syndrome caused by, 577 (Apr.)
monoclonal paraproteinemia with subacute encephalopathy, scleromyxedema and, 1054 (June)
natalen, characterization and classification of, 1837 (Dec.)
partial, controlled study of progabide in, methodology and results, 963 (June)
pharmacology, phenytoin and carbamazepine, alone and in combination, anticonvulsant and neurotoxic effects, 1111 (July)
progesterone therapy for (Correspondence), 1435 (Aug.)
psychotropic medications, effect of, on control of, in patients with epilepsy, 1525 (Sept.)
refractory status epilepticus, pentobarbital treatment of, 500 (Mar.)
serial, lorazepam in childhood status epilepticus and, effectiveness and tachyphylaxis, 190 (Feb.)
somatotropin evoked potentials, cortical generators of, to median nerve stimulation, 1141 (July)
Sturge-Weber-Dimitri disease, without facial nevus, 1063 (June)
subacute sclerosing panencephalitis, intraventricular alpha 2b interferon for (Clinical/Scientific Note), 1884 (Dec.)
temporal lobectomy, seizure characteristics, pathology, and outcome after, 405 (Mar.)

Shy-Drager syndrome
size-dependent myelinated fiber loss in the corticospinal tract in, and amyotrophic lateral sclerosis, 529 (Mar.)

Simultaneous diagnosis
attention, perception, and eye movements in, 1642 (Oct.)

Skeletal fracture
history of, amyotrophic lateral sclerosis and, case-control study, 717 (Apr.)

Skin
biopsy, immunoglobulin deposits in peripheral nerve endings detected by, in patients with IgM M proteins and neuropathy, 303 (Feb.)
incontinentia pigmenti, anterior horn cell degeneration association with, 446 (Mar.)
scleromyxedema, monoclonal paraproteineinemia with subacute encephalopathy, seizures and, 1054 (June)

Sleep disorders
apnea, mitochondrial encephalomyelopathy, ataxia and (Clinical/Scientific Note), 1429 (Aug.)
apnea syndrome, bimodality electrophysiologic evaluation of brainstem in, 1036 (June)
Leigh’s disease, sleep studies and, automatic respiratory failure, case report, 1876 (Dec.)
narcolepsy, clinical and sleep laboratory study of symptoms of, in multiple sclerosis, 683 (Apr.)
narcolepsy, HLA antigens in, 1885 (Dec.)
narcolepsy, monogenic twins (Clinical/Scientific Note), 1089 (June)

Smell
results of National Geographic olfaction survey available, 27A (Dec.)

Smoking habits
Multiple sclerosis, and central nervous system, 1887 (Dec.)
Parkinson’s disease, idiopathic and other illnesses in, case-control study of, 1226 (Feb.)

Somatosensory activation
human task-specific, 1301 (Aug.)
Somatosensory evoked potentials: See also Evoked potentials

Somatostatin
cerebrospinal fluid, multiple sclerosis, reversible loss of diurnal oscillation in relapses, 1060 (June)

Sparase
dermatomal, due to cerebellopontine angle lesion, case report, 337 (Feb.)

Spastic paraparesis
urethral nerve stimulation and motor control of tibialis anterior muscle in, 121 (July)

Spatial disorientation
Parkinson's disease, early symptom of, 485 (Mar.)

Speech
without conscious awareness, 882 (Apr.)

Spina bifida
first description of, by Nicolas Tulp (Historical Neurology), 1816 (Nov.)

Spinal cord
abscess, crural, 1747 (Nov.)

Stereotaxic
myelotomy, cranial magnetic resonance imaging in the evaluation of, 1038 (June)

Stenosis
basilar artery, middle and distal segments, 1742 (Nov.)

Steroids
hibernation, global, without hemiparesis, multiple etiologies, 201 (Feb.)

Stroke
acute, hypercoagulability in, 2667 (Oct.)
aphasia, global, without hemiparesis, multiple etiologies, 201 (Feb.)
artery-to-artery embolism causing, in the posterior circulation, 292 (Feb.)
cocaine-associated, "crack," 1489 (Dec.)
cramp-associated (coca) (Correspondence), 1092 (June)
epilepsy after, 1092 (June)
evaluation of, using electroencephalography frequency analysis and topographic mapping, 1153 (July)
magnetic resonance imaging in, sensitivity and specificity of, 1586 (Oct.)
Mycoplasma pneumoniae infection, in a young adult, complicated by intravascular coagulation (Clinical/Scientific Note), 1430 (Aug.)
right hemisphere, reduction in cerebral activation after, 957 (June)
risk factor assessment, new approach, lipoprotein(a) in ischemic cerebrovascular disease, 513 (Mar.)
right hemisphere, severe dysarthria with, 1061 (June)
retinal, EMG in (Correspondence), 1434 (Aug.)
significant data, 1542 (Sept.)
negative data, 749 (May)

Thalamic
myoclonus, physostigmine-induced, in Alzheimer's disease, 345 (Feb.)
without conscious awareness, 682 (Apr.)

Thalidomide
first description of, by Nicolas Tulp (Historical Neurology), 1816 (Nov.)

Thalidomide-resistant
myelopathy, cranial magnetic resonance imaging in the evaluation of, 1038 (June)

Thermometer
without conscious awareness, 682 (Apr.)

Thiamine
myoclonus, physostigmine-induced, in Alzheimer's disease, 345 (Feb.)
without conscious awareness, 682 (Apr.)

Thompson's disease
hemifacial, due to contralateral acoustic neuroma, case report, 339 (Feb.)
myoclonic, pyrithioxine-induced, in Alzheimer's disease, 345 (Feb.)

Thyroid hormone
amyotrophic lateral sclerosis and (Letter), 175 (Jan.)
amyotrophic lateral sclerosis, treatment of, with the TRH analog DN-1417, 715 (Apr.)
intrathecal, pharmacokinetics of, 597 (Apr.)

Tic disorders
gilles de la Tourette's syndrome, rating scale for, description, reliability, and validity data, 1542 (Sept.)

Tick bite
meningoradiculoneuritis, clinical, electrophysiologic, and histologic findings in 10 cases, 749 (May)

Tinnitus
gaze-evoked, 1038 (June)
Tolosa-Hunt syndrome
asymmetric cavernous sinus not necessarily pathologic (Letter), 175 (Jan.)
ophthalmoplegia, steroid-responsive painful, not always sign of (Letter), 1544 (Mar.)

Toluene
abuse of, and neurologic impairment (Letter), 356 (Feb.)

Toxemia
cerebral vasodilatation in, 1555 (Sept.)

Toxins
botulinum A, for cranial-cervical dystonia, double-blind, placebo-controlled study, 616 (Apr.)
cocaine, crack-associated stroke (Correspondence), 1092 (June)
cyclosporin A toxicity, cerebral blindness and encephalopathy with, 1072 (June)
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding, in humans, 1575 (Oct.)
multiple sclerosis, workplace and, report of an industry-based cluster, zinc and, 1672 (Oct.)
neurotoxic disease, recognition of, 276 (Feb.)
neurotoxicity, delayed, after ingestion of carbamate pesticide, 1229 (July)
paraplegia, Parkinson's disease and (Correspondence), 1820 (Nov.)
paraplegia, Parkinson's disease and (Correspondence), 728 (April)
phenelzine, responsive to dantrolene, 865 (May)
rattlesnake venom-induced myokymia, evidence for peripheral nerve origin, 1545 (Sept.)
toluene abuse, neurologic impairment and (Letter), 356 (Feb.)

Tranexamic acid
acetazolamide-responsive, 488 (Mar.)

Transection of, orthostatic hypotension-induced autonomic dysreflexia, 1221 (July)

vascular malformations of, intrathecal perimedullary arterovenous fistulas fed by medullary arteries, 969 (June)

Spinal muscular atrophy
extracts of muscle biopsies from patients with, inhibit neurite outgrowth from spinal neurons, 1361 (Aug.)

Stones
hemifacial, due to cerebellopontine angle lipoma, case report, 337 (Feb.)
cerebrospinal fluid, multiple sclerosis, reversible loss of diurnal oscillation in relapses, 1060 (June)

Subacute sclerosing panencephalitis
evidence for peripheral nerve origin, 1545 (Sept.)
toluene abuse, neurologic impairment and (Letter), 356 (Feb.)

Trombotic
amyotrophic lateral sclerosis and (Correspondence), 1266 (July)
head, human mesencephalon, altered striatal dopaminergic metabolism 36 hours after, 322 (Feb.)

Tremor
caffeine and, 169 (Jan.)

Tremor
effective, review of, 1194 (July)

Tremor
effective, review of, 1194 (July)

Trigeminal
ganglia neurons
degeneration of, caused by retrograde axonal transport of doxorubicin, 985 (June)

Trigeminal
effect of, on muromuscular transmission, Parkinson's disease and myasthenia gravis, 832 (May)
olivoponto cerebellar atrophy, skeletal myokymia in, treatment with, 1258 (July)

Trimethylamin
acute limbic-cerebellar syndrome, 945 (June)

Systemic lupus erythematosus
cerebral blood flow in, with or without cerebral complications, 1596 (Oct.)

Tears
oligoclonal IgG in, 853 (May)

Terferon
Parkinson's disease, animal models of, mixed dopamine agonist-antagonist, 723 (Apr.)

Testosterone
levels of, in adult male epileptic patients, 706 (Apr.)

Thomson's disease
myasthenia congenita, acetylcholinelike-responsive, 488 (Mar.)

Thyroid
ophthalmopathy, minimal, 1803 (Nov.)

Thyrotropin-releasing hormone
amyotrophic lateral sclerosis and (Letter), 175 (Jan.)

Trimethyltin
acute limbic-cerebellar syndrome, 945 (June)

Type 1 diabetes
hemifacial, due to cerebellopontine angle lipoma, case report, 337 (Feb.)
neurosyphilis, penicillin concentrations in serum and CSF during high-dose intravenous treatment for, 1214 (July)

Tolosa-Hunt syndrome
asymmetric cavernous sinus not necessarily pathologic (Letter), 175 (Jan.)
ophthalmoplegia, steroid-responsive painful, not always sign of (Letter), 544 (Mar.)

Toluene
abuse of, and neurologic impairment (Letter), 356 (Feb.)

Toxemia
cerebral vasodilatation in, 1555 (Sept.)

Toxins
botulinum A, for cranial-cervical dystonia, double-blind, placebo-controlled study, 616 (Apr.)
cocaine, crack-associated stroke (Correspondence), 1092 (June)
cyclosporin A toxicity, cerebral blindness and encephalopathy with, 1072 (June)
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding, in humans, 1575 (Oct.)
multiple sclerosis, workplace and, report of an industry-based cluster, zinc and, 1672 (Oct.)
neurotoxic disease, recognition of, 276 (Feb.)
neurotoxicity, delayed, after ingestion of carbamate pesticide, 1229 (July)
paraplegia, Parkinson's disease and (Correspondence), 1820 (Nov.)
paraplegia, Parkinson's disease and (Correspondence), 728 (April)
phenelzine, responsive to dantrolene, 865 (May)
rattlesnake venom-induced myokymia, evidence for peripheral nerve origin, 1545 (Sept.)
toluene abuse, neurologic impairment and (Letter), 356 (Feb.)

Tranexamic acid
acetazolamide-responsive, 488 (Mar.)

Trigeminal
ganglia neurons
degeneration of, caused by retrograde axonal transport of doxorubicin, 985 (June)

Trigeminal
effect of, on muromuscular transmission, Parkinson's disease and myasthenia gravis, 832 (May)
olivoponto cerebellar atrophy, skeletal myokymia in, treatment with, 1258 (July)

Trimethylamin
acute limbic-cerebellar syndrome, 945 (June)

December 1987 NEUROLOGY 37 1911
Tropical spastic paraparesis
Seychelles Islands, clinical and case-control neuroepidemiologic study, 1323 (Aug.)

Tuberculosis
central nervous system, transient neurologic deficit as a presentation of
(Clinical/Scientific Note), 1884 (Dec.)

Twin studies
Alzheimer's disease, clinical and family study of 22 twin pairs, 359 (Mar.)
muscular dystrophy, Duchenne, monozygotic female twin carriers discordant for the clinical manifestations of, 1147 (July)
narcolepsy (Clinical/Scientific Note), 1089 (June)

U

Ultrasonography
schwannoma diagnosis by (Clinical/Scientific Note), 1817 (Nov.)

Urine
myoglobinuric, recurrent, exercise-induced, defective activity of inner carnitine
palmitoyltransferase in muscle mitochondria of two patients, 1184 (July)

V

Valproate
clinical toxicity of, induced by acetylsalicylic acid, 1392 (Aug.)
lactate/pyruvate interactions with (Correspondence), 1887 (Oct.)

Valproic acid
fatal hepatotoxicity, retrospective review, 379 (Mar.)
hepatotoxicity of, transitional polytherapy, liver enzymes, and, 1692 (Oct.)
substitution of Depakene (Abbott) with generic product, breakthrough seizures in (Clinical/Scientific Note), 1885 (Dec.)

Vascular dementia: See also Dementia
magnetic resonance imaging in, 29 (Jan.)

Vegetative state
ethics, Brophy case, 1357 (Aug.)
ethics, Brophy case (Editorial), 1359 (Aug.)
Ventricular enlargement
rate of, in dementia of the Alzheimer type correlates with rate of neuro-
psychological deterioration, 1135 (July)

Vertigo
benign positional, clinical and oculographic features in 240 cases, 371 (Mar.)
flunarizine- and cinnarizine-induced extrapyramidal reactions, 881 (May)

Wilson's disease
radiology, 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomogra-
phy studies of, 1707 (Nov.)

Y

Yohimbine
oral, in human autonomic failure, 215 (Feb.)

Z

Zinc
multiple sclerosis, workplace and, report of an industry-based cluster, 1672 (Oct.)